Prospects for Johnson & Johnson's HIV vaccine effort have looked shaky since one of its shots failed to protect women in sub-Saharan Africa against infection with the virus in a phase 2
Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help prevent HIV infection, thanks to positive data from a phase 1/2a trial.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio